Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | APOB | P04114 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 1/20 | 0.43 |
| ▸ | MTTP | P55157 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083646 | 0.90 | GAA (0.49) | GAAHTR2CHTR2AHTR2BNPC1 | |
| SCHEMBL6793010 | 0.90 | HTR2C (0.50) | SMOAPOBGAAHTR2CHTR2A | |
| SCHEMBL6796059 | 0.87 | SMO (0.58) | SMOAPOBHTR2CHTR2AHTR2B | |
| SCHEMBL6799425 | 0.87 | MTTP (0.49) | SMOAPOBGAAHTR2CHTR2A | |
| SCHEMBL6795217 | 0.82 | SMO (0.47) | SMOAPOBGAAPTGS1UGCG | |
| SCHEMBL6787209 | 0.82 | PTGS1 (0.51) | SMOAPOBPTGS1MTTP | |
| SCHEMBL6791861 | 0.82 | PTGS1 (0.51) | SMOAPOBPTGS1MTTPKIT | |
| SCHEMBL6795238 | 0.81 | SMO (0.47) | SMOAPOBGAAPTGS1UGCG | |
| SCHEMBL6805247 | 0.81 | MTTP (0.49) | SMOAPOBGAAMTTPNPC1 | |
| SCHEMBL6499436 | 0.81 | RAB9A (0.46) | SMOAPOBGAAHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885APOB 1/4885GAA 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.